Murali Gopalakrishnan
Overview
Explore the profile of Murali Gopalakrishnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
1365
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Su Z, Widomski D, Nikkel A, Leys L, Namovic M, Donnelly-Roberts D, et al.
J Basic Clin Physiol Pharmacol
. 2018 Feb;
29(3):281-290.
PMID: 29397387
Background: Losartan, a blocker of the angiotensin II type I receptor, is an important part of the standard of care for diabetic nephropathy (DN). The obese ZSF-1 rats display many...
2.
McGaraughty S, Davis-Taber R, Zhu C, Cole T, Nikkel A, Chhaya M, et al.
J Am Soc Nephrol
. 2017 Aug;
28(12):3616-3626.
PMID: 28827403
Targeted delivery of a therapeutic agent to a site of pathology to ameliorate disease while limiting exposure at undesired tissues is an aspirational treatment scenario. Targeting diseased kidneys for pharmacologic...
3.
Zhu C, Gopalakrishnan S, Doyle K, Nikkel A, Olson L, Abraham V, et al.
Eur J Pharmacol
. 2016 Jun;
788:1-11.
PMID: 27288879
Adenosine (ADO) is an important regulatory purine nucleoside that accumulates at sites of inflammation and tissue injury including in diseases associated with renal pathology. Endogenous levels of ADO may be...
4.
Gopalakrishnan M, Rampe D, Triggle C
Biochem Pharmacol
. 2015 Aug;
98(2):267-8.
PMID: 26307541
No abstract available.
5.
Rampe D, Gopalakrishnan M
Biochem Pharmacol
. 2015 Aug;
98(2):292-8.
PMID: 26254590
This Festschrift contribution summarizes the perspectives of two of David Triggle's graduate students. Both share somewhat parallel scientific and career paths-i.e., enrolling in the Biochemical Pharmacology program at the University...
6.
Decker M, Gopalakrishnan M, Meyer M
Expert Opin Drug Discov
. 2013 Mar;
3(9):1027-40.
PMID: 23506178
Background: Nicotine has a variety of effects in humans and in experimental animals that are suggestive of therapeutic potential. However, nicotine has a variety of adverse effects that preclude its...
7.
Liguori M, Lee C, Liu H, Ciurlionis R, Ditewig A, Doktor S, et al.
Front Genet
. 2012 Nov;
3:213.
PMID: 23112805
Xenobiotic-mediated induction of cytochrome P450 (CYP) drug metabolizing enzymes (DMEs) is frequently encountered in drug discovery and can influence disposition, pharmacokinetic, and toxicity profiles. The CYP1A subfamily of DMEs plays...
8.
Radek R, Robb H, Stevens K, Gopalakrishnan M, Bitner R
J Pharmacol Exp Ther
. 2012 Sep;
343(3):736-45.
PMID: 22988063
Nicotinic acetylcholine receptor (nAChR) agonists improve sensory gating deficits in animal models and schizophrenic patients. The aim of this study was to determine whether the novel and selective α7 nAChR...
9.
Schrimpf M, Sippy K, Briggs C, Anderson D, Li T, Ji J, et al.
Bioorg Med Chem Lett
. 2012 Jan;
22(4):1633-8.
PMID: 22281189
The well-known interferon-inducer tilorone was found to possess potent affinity for the agonist site of the α7 neuronal nicotinic receptor (K(i)=56 nM). SAR investigations determined that both basic sidechains are...
10.
Kohlhaas K, Bitner R, Gopalakrishnan M, Rueter L
Psychopharmacology (Berl)
. 2011 Nov;
220(4):823-33.
PMID: 22038534
Rationale: Antipsychotics normalize responses in the DBA/2 mouse model of prepulse inhibition (PPI), a preclinical model of sensorimotor gating deficits. The α7 nicotinic acetylcholine receptor (nAChR) as a molecular target...